HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Heo, Y. S. Articles by Kang, Y.-K. Search for Related Content PubMed PubMed Citation Articles by Heo, Y. S. Articles by Kang, Y.-K. Social Bookmarking                   What's this?

Hand-Foot Syndrome in Patients Treated With Capecitabine-Containing Combination Chemotherapy

From the Department of Pharmacy, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (Y. S. Heo); Division of Hematology-Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (H. M. Chang, T. W. Kim, M.-H. Ryu, J.-H. Ahn, S. B. Kim, J. S. Lee, W. K. Kim, Y.-K. Kang); and the Graduate School of Clinical Health Sciences, Ewha Womans University, Seoul, Korea (Y. S. Heo, H. K. Cho).

Clinical characteristics and risk factors of hand-foot syndrome were investigated in patients who received capecitabine-containing chemotherapy. Toxicity data were analyzed from 179 patients in 4 prospective clinical trials testing docetaxel/capecitabine/cisplatin in stomach cancer, capecitabine/cisplatin in biliary or stomach cancer, and vinorelbine/capecitabine in breast cancer. Hand-foot syndrome was reported in 116/179 (64.8%) of patients, with grade 3 hand-foot syndrome in 8/179 (4.5%). Hand-foot syndrome first developed within the first 3 chemotherapy cycles in 100/116 (86.2%) patients, with the median onset for all 3 treatment regimens occurring during cycle 2. Because severe reactions were rare, hand-foot syndrome was not a major factor influencing treatment schedule. Risk factor analyses showed that combined use of docetaxel and preceding chemotherapy-related stomatitis were significant risk factors for the development of hand-foot syndrome. Our results suggest that a combined treatment agent and a patient's susceptibility to chemotherapy-related toxicity may increase the risk of capecitabine-induced hand-foot syndrome.

Key Words: Capecitabine • hand-foot syndrome • docetaxel • cisplatin • vinorelbine

Address for reprints: Yoon-Koo Kang, MD, Division of Hematology-Oncology, Department of Internal Medicine, Asan Medical Center, 388-1 Pungnapdong, Songpa-gu, Seoul, Korea 138-736.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. M Gressett, B. L Stanford, and F. Hardwicke Management of hand-foot syndrome induced by capecitabine Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 131 - 141. [Abstract] [PDF]

				F. Scotte, J.-M. Tourani, E. Banu, M. Peyromaure, E. Levy, S. Marsan, E. Magherini, E. Fabre-Guillevin, J.-M. Andrieu, and S. Oudard Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand J. Clin. Oncol., July 1, 2005; 23(19): 4424 - 4429. [Abstract] [Full Text] [PDF]